ArticleCancer cytopathology2015
Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Article in Cancer cytopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review.Frontiers in oncology · 2026Pooled it
- Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.BMC cancer · 2019Trial
- Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.Cancer cytopathology · 2026Article
- ZIPcnv: accurate and efficient inference of copy number variations from shallow whole-genome sequencing.Bioinformatics (Oxford, England) · 2025Article
- PangenomeX: a graph convolutional network-based pangenome framework for unbiased population-scale genomic variation analysis.Briefings in bioinformatics · 2025Article
- SAMURAI: shallow analysis of copy number alterations using a reproducible and integrated bioinformatics pipeline.Briefings in bioinformatics · 2024Article
- Molecular and functional landscape of malignant serous effusions for precision oncology.Nature communications · 2024Article
- Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.Cancer research · 2022Article
- Practice guidelines forJournal of medical genetics · 2022Review
- Radiomics and radiogenomics in ovarian cancer: a literature review.Abdominal radiology (New York) · 2021Review
- Molecular testing on serous effusion: An update.CytoJournal · 2021Review
- Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.Blood advances · 2020Article
- Molecular Profiling of Malignant Pleural Effusions with Next Generation Sequencing (NGS): Evidence that Supports Its Role in Cancer Management.Journal of personalized medicine · 2020Review
- Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer.Oncology letters · 2020Article
- Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.PloS one · 2020Article
- Invited review-next-generation sequencing: a modern tool in cytopathology.Virchows Archiv : an international journal of pathology · 2019Review
- WisecondorX: improved copy number detection for routine shallow whole-genome sequencing.Nucleic acids research · 2019Article
- Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2018Article
- Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Oncology letters · 2017Article
- The Role of Liquid Based Cytology and Ancillary Techniques in the Peritoneal Washing Analysis: Our Institutional Experience.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMutation analysis for personalized treatment has become increasingly important in the management of different types of cancer. The advent of new DNA extraction protocols and sequencing platforms with reduced DNA input requirements might allow the use of cytology specimens for high-throughput mutation analysis. In this study, the authors evaluated the use of effusion fluid for next-generation sequencing-based, multigene mutation profiling.
methodsFour specimens from each of 5 patients who had at least stage III, high-grade serous ovarian carcinoma were selected: effusion fluid; frozen tumor; formalin-fixed, paraffin embedded tumor; and matched normal blood. Frozen tumors from each patient were previously characterized by The Cancer Genomic Atlas (TCGA). DNA was extracted from all specimens and was sequenced using a custom hybridization capture-based assay. Genomic alterations were compared among all specimens from each patient as well as with mutations reported in TCGA for the same tumors.
resultsIn total, 17 distinct somatic mutations were identified in the cohort. Ten of 17 mutations were reported in TCGA and were called in all 3 malignant specimens procured from the patients. Of the remaining 7 mutations, 2 were called in all 3 specimens, and the other 5 were sample-specific. Two mutations were detected only in the cytology specimens. Copy number profiles were concordant among the tumors analyzed.
conclusionsCytology specimens represent suitable material for high-throughput sequencing, because all mutations described by TCGA were independently identified in the effusion fluid. Differences in mutations detected in samples procured from the same patient may reflect tumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.